Imunon is a clinical-stage company developing IMNN-001, an IL-12 DNA immunotherapy given into the abdomen with chemotherapy for newly diagnosed advanced ovarian cancer; it is not approved.
Imunon's case rests on IMNN-001, an immunotherapy given into the abdomen with chemotherapy for newly diagnosed advanced ovarian cancer. In the randomized Phase 2 OVATION 2 trial of 112 women, median overall survival was 45.1 months versus 30.4 months on chemotherapy alone. Phase 3 OVATION 3 should finish enrolling in the first half of 2029. Cash was $6.9 million at June 30, and Imunon has disclosed substantial doubt about continuing as a going concern.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Imunon raises money to keep OVATION 3 enrolling
Does Imunon secure enough funding to keep OVATION 3 enrolling through 2027?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Imunon is enrolling its Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer faster than planned, after Phase 2 showed median survival 14.7 months longer; cash of $6.9 million and a going-concern warning make funding the main risk
IMNN-001's Phase 2 OS benefit sets up Phase 3 OVATION 3 as the binary that determines whether this ovarian cancer bet pays off
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Breast and gynecologic cancers
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
8 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.